Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2/Phase 3

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

NCT ID: NCT03435796Sponsor: CelgeneLast updated: 2026-06-02

Summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Arms & interventions

  • GeneticGene-modified (GM) T cell therapy

    No investigational product will be administered

Outcome measures

Primary

  • Incidence of delayed Adverse Events (AEs)

    Time frame: Up to 15 years from last gene-modified (GM) T cell infusion

  • Persistence of GM T cell drug products

    Time frame: Up to 15 years from last GM T cell infusion

  • Analysis of vector integration sites

    Time frame: Up to 15 years from last GM T cell infusion

  • Incidence of replication-competent lentiviruses

    Time frame: Up to 15 years from last GM T cell infusion

  • Physical growth as assessed by physical examination (pediatric participants only)

    Time frame: Up to 15 years from last GM T cells infusion or until Tanner Stage 5 is reached

  • Incidence of sexual maturation as assessed by the Tanner staging system (pediatric participants only)

    Time frame: Up to 15 years from last GM T cells infusion or until Tanner Stage 5

  • Proportion of participants who progressed on the study: participants with original diagnosis of malignancies

    Time frame: Up to 15 years from last GM T cells infusion

  • Overall Survival (participants with original diagnosis of malignancies)

    Time frame: Up to 15 years from last GM T cells infusion

Secondary

  • Lymphocyte count (B-cell)

    Time frame: Up to 15 years

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Inclusion Criteria: * Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable. * Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted. Exclusion Criteria: Not Applicable Other protocol-defined inclusion/exclusion criteria apply

Study locations (100)

University of Alabama Birmingham

Birmingham, Alabama, 10016

Recruiting
Luciano Costa, Site 01171 · Contact

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

Recruiting
Rajneesh Nath, Site 01049 · Contact

Mayo Clinic Phoenix

Phoenix, Arizona, 85054

Recruiting
Jeremy Larsen, Site 01200 · Contact

Local Institution - 01039

Scottsdale, Arizona, 85258

Completed

Local Institution - 01021

Tucson, Arizona, 85724

Withdrawn

City Of Hope

Duarte, California, 91010

Recruiting
Tanya Siddiqi, Site 01011 · Contact

University Of California San Diego Moores Cancer Center

La Jolla, California, 92093

Recruiting
Thomas Kipps, Site 01019 · Contact

Local Institution - 01206

Los Angeles, California, 90048

Withdrawn

Local Institution - 01043

Sacramento, California, 95816

Withdrawn

University of California, San Francisco- California

San Francisco, California, 94143

Recruiting
Charalambos Andreadis, Site 01108 · Contact

UCLA Medical Centre-Santa Monica

Santa Monica, California, 90095

Recruiting
Sarah Larson, Site 01184 · Contact

Stanford Cancer Center

Stanford, California, 94305

Recruiting
Michaela Liedtke, Site 01119 · Contact

University Of Colorado Cancer Center

Aurora, Colorado, 80045

Recruiting
Manali Kamdar, Site 01208 · Contact

Colorado Blood Cancer Institute

Denver, Colorado, 80218

Recruiting
Tara Gregory, Site 01212 · Contact

Yale Cancer Center

New Haven, Connecticut, 06520

Recruiting
Iris Isufi, Site 01059 · Contact

Local Institution - 01050

Washington D.C., District of Columbia, 20007

Withdrawn

The Mayo Clinic - Jacksonville, Davis-E

Jacksonville, Florida, 32224

Recruiting
Sikander Ailawadhi, Site 01201 · Contact

Baptist Cancer Center

Miami, Florida, 33176

Recruiting
Yuliya Linhares, Site 01047 · Contact

Local Institution - 01035

Orlando, Florida, 32804

Completed

H. Lee Moffitt Cancer Center and Research Institute University of South Florida

Tampa, Florida, 33612

Recruiting
Melissa Alsina, Site 01153 · Contact

Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322

Recruiting
Sagar Lonial, Site 01103 · Contact

Northside Hospital, Inc

Atlanta, Georgia, 30342

Recruiting
Scott Solomon, Site 01207 · Contact

Northwestern Memorial Hospital

Chicago, Illinois, 60611

Recruiting
Reem Karmali, Site 01014 · Contact

University Of Chicago Medical Center

Chicago, Illinois, 60637-1447

Recruiting
Peter Riedell, Site 01018 · Contact

Local Institution - 01040

Maywood, Illinois, 60153

Withdrawn

Local Institution - 01063

Niles, Illinois, 60714

Withdrawn

IN Univ Simon Cancer Center

Indianapolis, Indiana, 46202

Recruiting
Rafat Abonour, Site 01161 · Contact

Franciscan Health Indianapolis

Indianapolis, Indiana, 46237

Recruiting
Anand Tandra, Site 01217 · Contact

Local Institution - 01020

Indianapolis, Indiana, 46237

Completed

Kansas University Medical Center

Westwood, Kansas, 66205

Recruiting
Al-Ola Abdallah, Site 01174 · Contact

Cancer Center of Kansas

Wichita, Kansas, 67214

Recruiting
Bassam Mattar, Site 01031 · Contact

University Of Kentucky

Lexington, Kentucky, 40536

Recruiting
Chaitanya Iragavarapu, Site 01046 · Contact

Norton Cancer Institute Louisville Oncology

Louisville, Kentucky, 40207

Recruiting
Don Stevens, Site 01032 · Contact

Local Institution - 01026

New Orleans, Louisiana, 70112

Withdrawn

University of Maryland - Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201

Recruiting
Mehmet Kocoglu, Site 01164 · Contact

Sidney Kimmel Comp Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231

Recruiting
Syed Abbas Ali, Site 01017 · Contact

National Cancer Institute

Bethesda, Maryland, 20892-1203

Recruiting
James Kochenderfer, Site 01114 · Contact

Local Institution - 01107

Boston, Massachusetts, 02114

Withdrawn

Massachusetts General Hospital / Dana-Farber Cancer Institute

Boston, Massachusetts, 02114

Recruiting
Jeremy Abramson, Site 01012 · Contact

Local Institution - 01106

Boston, Massachusetts, 02115

Withdrawn

University Of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

Recruiting
Monalisa Ghosh, Site 01024 · Contact

Karmanos Cancer Center Wayne State University

Detroit, Michigan, 48201

Recruiting
Abhinav Deol, Site 01025 · Contact

Providence Cancer Institute

Southfield, Michigan, 48075

Recruiting
Leo Reap, Site 01056 · Contact

M Health Fairview University of Minnesota Medical Center - East Bank

Minneapolis, Minnesota, 55455

Recruiting
Veronika Bachanova, Site 01112 · Contact

Mayo Clinic

Rochester, Minnesota, 55905

Recruiting
Yi Lin, Site 01105 · Contact

Siteman Cancer Center

St Louis, Missouri, 63110

Recruiting
Ravi Vij, Site 01176 · Contact

University Of Nebraska Medical Center

Omaha, Nebraska, 68198-6840

Recruiting
Matthew Lunning, Site 01015 · Contact

Local Institution - 01030

East Brunswick, New Jersey, 08816

Completed

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Recruiting
David Siegel, Site 01102 · Contact

Morristown Memorial Hosp

Morristown, New Jersey, 07962

Recruiting
Mohamad Cherry, Site 01027 · Contact

Local Institution - 01053

New Brunswick, New Jersey, 08903

Withdrawn

New York Oncology Hematology P.C.

Albany, New York, 12206

Recruiting
Courtney Bellomo, Site 01041 · Contact

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Francisco Hernandez-Ilizaliturri, Site 01111 · Contact

Local Institution - 01066

New York, New York, 10016

Withdrawn

New York University - Langone Medical Center - The Center for Musculoskeletal Care

New York, New York, 10016

Recruiting
Amit Saxena, Site 01070 · Contact

Weill Cornell Medicine / New York Presbyterian Hospital

New York, New York, 10021

Recruiting
Roger Niles Pearse, Site 01198 · Contact

Icahn School Of Medicine At Mount Sinai

New York, New York, 10029

Recruiting
Sundar Jagannath, Site 01109 · Contact

Columbia University Medical Center/New York-Presbyterian Hospital

New York, New York, 10032

Recruiting
Ran Reshef, Site 01209 · Contact

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Maria Palomba, Site 01177 · Contact

Local Institution - 01051

Rochester, New York, 14642

Withdrawn

The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599

Recruiting
Saira Sheikh, Site 01071 · Contact

Levine Cancer Institute

Charlotte, North Carolina, 28204

Recruiting
Bei Hu, Site 01204 · Contact

Duke University Medical Center

Durham, North Carolina, 27705

Recruiting
Taewoong Choi, Site 01175 · Contact

Novant Health

Salisbury, North Carolina, 28147

Recruiting
Alan Skarbnik, Site 01058 · Contact

Oncology Hematology Care, Inc.

Cincinnati, Ohio, 45242

Recruiting
James Essell, Site 01037 · Contact

University Hospitals of Cleveland

Cleveland, Ohio, 44106-5000

Recruiting
Leland Metheny, Site 01042 · Contact

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Recruiting
Brian Hill, Site 01062 · Contact

Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute

Columbus, Ohio, 43210

Recruiting
Srinivas Devarakonda, Site 01074 · Contact

University of Oklahoma Peggy and Charles Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104

Recruiting
Adam Asch, Site 01038 · Contact

Willamette Valley Cancer Institute

Eugene, Oregon, 97401

Recruiting
Jeff Sharman, Site 01052 · Contact

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Stacy Lewis, Site 01028 · Contact

Oregon Health and Science University OHSU

Portland, Oregon, 97239

Recruiting
Richard Maziarz, Site 01022 · Contact

Children's Hospital of Philadelphia-Center for Childhood Cancer Research

Philadelphia, Pennsylvania, 19104

Recruiting
Stephan Grupp, Site 01061 · Contact

University of Pennsylvania Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104

Recruiting
Stephen Schuster, Site 01016 · Contact

Thomas Jefferson University - Clinical Research Institute

Philadelphia, Pennsylvania, 19107

Recruiting
Xia Bi, Site 01173 · Contact

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

Recruiting
Asya Varshavsky-Yanovsky, Site 01172 · Contact

UPMC Cancer Pavillion

Pittsburgh, Pennsylvania, 15232

Recruiting
Alison Sehgal, Site 01210 · Contact

Hematology and Oncology Associates of SC, LLC

Greenville, South Carolina, 29615

Recruiting
Saeeda Chowdhury, Site 01034 · Contact

Local Institution - 01064

Sioux Falls, South Dakota, 57105

Withdrawn

Sarah Cannon Research Inst

Nashville, Tennessee, 37203

Recruiting
Jesus Berdeja, Site 01101 · Contact

Texas Oncology

Dallas, Texas, 75230

Recruiting
Jay Courtright, Site 01044 · Contact

Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246

Recruiting
Houston Holmes, Site 01180 · Contact

UT Southwestern Medical Center

Dallas, Texas, 75390

Recruiting
Larry Anderson, Site 01104 · Contact

The University of Texas Health Science Center at Houston

Houston, Texas, 77030

Recruiting
Maureen Mayes, Site 01215 · Contact

University of Texas- MD Anderson

Houston, Texas, 77030

Recruiting
Hun Lee, Site 01013 · Contact

Sam Clinical Research Center

San Antonio, Texas, 78229

Recruiting
Paul Shaughnessy, Site 01211 · Contact

Local Institution - 01033

Temple, Texas, 76508

Withdrawn

Local Institution - 01054

Tyler, Texas, 75702

Completed

University of Utah - Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Recruiting
Douglas Sborov, Site 01199 · Contact

Intermountain Healthcare - LDS Hospital

Salt Lake City, Utah, 84143

Recruiting
Dannish Hoda, Site 01029 · Contact

University Of Virginia Health System

Charlottesville, Virginia, 22903

Recruiting
Indumathy Varadarajan, Site 01065 · Contact

Local Institution - 01045

Norfolk, Virginia, 23502

Completed

Local Institution - 01023

Richmond, Virginia, 23298

Withdrawn

Swedish Cancer Institute

Seattle, Washington, 98104

Recruiting
Daniel Egan, Site 01166 · Contact

Local Institution - 01060

Seattle, Washington, 98105

Withdrawn

Fred Hutchinson Cancer Center

Seattle, Washington, 98109

Recruiting
Jordan Gauthier, Site 01110 · Contact

Local Institution - 01055

Tacoma, Washington, 98405

Withdrawn

University Of Wisconsin

Madison, Wisconsin, 53705

Recruiting
Natalie Callander, Site 01036 · Contact

Froedtert Hospital BMT Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Othman Akhtar, Site 01178 · Contact

Local Institution - 01069

Wauwatosa, Wisconsin, 53226

Not Yet Recruiting
Site 01069 · Contact

References

  • Abramson JS, Siddiqi T, Gordon LI, Lunning MA, Wang M, Arnason JE, Kamdar M, Maloney DG, Shadman M, Andreadis CB, Sehgal A, Solomon SR, Ghosh N, Hidalgo-Lopez JE, Wang J, Ding X, Ogasawara K, Singh A, Palomba ML. Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL. Blood. 2026 Jun 3:blood.2025032270. doi: 10.1182/blood.2025032270. Online ahead of print.(PubMed)
  • Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024 Feb 1;143(5):404-416. doi: 10.1182/blood.2023020854.(PubMed)